Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovateltide in neonatal hypoxic-ischemic encephalopathy
NCT05514340Phase 2Recruiting
- Sponsor
- Pharmazz, Inc.
- Start
- Sep 2023
- Primary completion
- Nov 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypoxic-ischemic encephalopathy (HIE) comparing Normal Saline + Standard of care with Sovateltide + Standard of care (2 arms). Primary endpoint: Percentage of patients with death or disability (moderate/severe) at 24 months. Started Sep 2023; status: recruiting.
02
Drugs
sovateltide
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT05514340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514340.